Astral Q1 FY27 Revenue Up 15.9% to ₹15,780 Million, EBIDTA Grows 25.8%
Astral Limited reported Q1 FY27 consolidated revenue of ₹15,780 million, up 15.9% YoY. EBIDTA grew 25.8% to ₹2,440 million. Plumbing revenue rose 10.1%, Paints & Adhesives revenue up 29.5%. The company acquired 60% of DSS for ₹391 million, expanding its specialty chemicals portfolio.
The announcement details significant financial growth and strategic expansion through acquisition, which are material events for investors and stakeholders, indicating a positive outlook for the company's future performance.
The company reported strong year-on-year growth in revenue and EBIDTA, with positive performance across its key business segments, including plumbing, paints, and adhesives. The strategic acquisition also adds a new growth avenue.
Astral Limited announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company reported a consolidated revenue from operations of ₹15,780 million, marking a 15.9% year-on-year growth. EBIDTA saw a significant increase of 25.8% to ₹2,440 million.
The Plumbing Business revenue grew by 10.1% to ₹10,505 million, with segment EBIDTA rising by 26.7% to ₹1,983 million, despite a weak industry demand scenario. The company highlighted its market share gains and a healthy EBIDTA margin of 18.9% in this segment. Production capacity for pipes and fittings was increased, and the new CPVC Resin plant Phase I is on schedule for completion by December 2026, with trial runs expected in Q4 FY27, aiming to boost market share and margins from FY28 onwards. The Bathware business also showed robust growth of 18.1%.
The Paints and Adhesives Business demonstrated strong performance, with revenue from operations increasing by 29.5% to ₹5,275 million and segment EBIDTA by 21.9% to ₹457 million. The Adhesive India Business achieved a 24.9% sales growth, with efforts underway to stabilize margins. The Adhesive Overseas Business grew by 26% with a positive EBIDTA margin of 4.9%. The Paints business experienced a remarkable 48.7% sales growth, reaching EBIDTA break-even.
Astral Limited also expanded its portfolio through the acquisition of a 60% partnership interest in Differentiated & Sustainable Solutions LLP (DSS) for ₹391 million, a move that contributes to the Specialty Chemicals segment and is expected to drive higher-value growth. DSS reported ₹67 million in sales revenue and ₹9 million in EBIDTA in its first quarter contribution.
What to do with a filing like this
Astral Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Astral Limited. Read the original for the full detail.